Meta-analysis
Open access
Oct 2026
CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis
CagriSema produces clinically meaningful additional weight loss and modest improvements in surrogate cardiometabolic measures compared with semaglutide 2.4 mg alone, at the cost of more frequent injection-site reactions and, at most, modestly more frequent gastrointestinal events.
Zehra Khatoon Rasool, Rajvi K. Shah, Ansharah E. Zinnia Batool et al.
· Frontiers in Endocrinology · 0 citations